Compare · NVO vs SEPN
NVO vs SEPN
Side-by-side comparison of Novo Nordisk A/S (NVO) and Septerna Inc. (SEPN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SEPN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $167.46B, about 91.2x SEPN ($1.84B).
- SEPN has been more active in the news (12 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 11 for SEPN).
- Company
- Novo Nordisk A/S
- Septerna Inc.
- Price
- -
- -
- Market cap
- $167.46B
- $1.84B
- 1M return
- -4.16%
- -
- 1Y return
- -20.63%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 9
- 12
- Recent ratings
- 25
- 11
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SEPN
- Chief Financial Officer Gil M Labrucherie sold $832,359 worth of shares (20,000 units at $41.62) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Finer Jeffrey exercised 18,500 shares at a strike of $2.76 and sold $807,015 worth of shares (18,500 units at $43.62) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Septerna Inc.
- Director Ezekowitz Alan sold $3,934,363 worth of shares (81,820 units at $48.09) as part of a pre-agreed trading plan, decreasing direct ownership by 70% to 35,600 units (SEC Form 4)
- SEC Form 144 filed by Septerna Inc.
- SEC Form 144 filed by Septerna Inc.
- SEC Form 10-Q filed by Septerna Inc.
- Septerna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results
- Septerna Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits